New Zealand markets close in 6 hours 36 minutes

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.24-0.32 (-2.20%)
At close: 04:00PM EST
14.24 0.00 (0.00%)
After hours: 04:09PM EST
Full screen
Trade prices are not sourced from all markets
Previous close14.56
Bid14.17 x 800
Ask14.23 x 800
Day's range14.14 - 14.71
52-week range10.81 - 21.25
Avg. volume874,431
Market cap589.78M
Beta (5Y monthly)1.13
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022

    MORRISTOWN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will participate in a fireside chat at Piper Sandler’s 34th Annual Healthcare Conference, taking place in person

  • GlobeNewswire

    Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

    First-in-human data shared at The Liver Meeting® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults Company announces severe alcohol-associated hepatitis (sAH), a disease with no approved therapies, as its lead indication for INT-787 Company initiates Phase 2a FRESH study in patients with sAH MORRISTOWN, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercia

  • GlobeNewswire

    Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022

    OCA 25 mg demonstrated double the response rate of placebo in reduction of liver fibrosis without worsening of NASH; consistent antifibrotic effect shown across multiple analyses OCA 25 mg showed increased antifibrotic efficacy in patients with advanced fibrosis without cirrhosis Robust safety assessment of 2,477 patients, including 1,000 on study drug for four years, supports chronic administration of OCA REGENERATE data to be presented in late-breaking oral session on Monday, November 7 Compan